CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 18 enrolled
Drug / intervention
fixed dose varenicline +1 moredrug
Likely dose
fixed dose varenicline 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00525837
NCT00525837N/ACompleted
CompareCT.gov

Systematic Assessment of Response to Open-label Treatment With Varenicline in Depressed Outpatient Smokers

Butler Hospital·interventional·Posted Sep 6, 2007·Updated Nov 28, 2018

In Brief

A clinical study evaluating fixed dose varenicline and varenicline for Depressive Disorder and Smoking. Completed, enrolled 18 participants across 1 site.

Detailed Summary

This study will assess whether varenicline (chantix) has antidepressant properties when used in addition to other psychiatric medication. It will also assess whether varenicline improves the inability to feel pleasure (i.e. anhedonia), and if it is well-tolerated when used with psychiatric medications. Enrolled patients will be assessed for improved mood, improved anhedonia, overall sense of health, side effects as well as tobacco use for 6-8 weeks. Medication will be provided free of charge.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder, Smoking
CountriesUnited States
CollaboratorsBrown University

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 6, 2007
Enrollment StartSep 1, 2007
Primary CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 18.8 years ago

Interventions

fixed dose vareniclinedrug

varenicline 0.5 mg po daily for days 1-3, 0.5 twice daily for days 4-7, 1 mg twice daily thereafter for study duration.

vareniclinedrug

up to 1 mg twice daily